{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:22:59Z","timestamp":1788841379319,"version":"build-2803163510"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Glomerular diseases may occur secondary to malignancies. Age-specific cancer screening is recommended for patients with glomerular diseases and may be extended based on the specific risk associated with the detected histopathologic pattern. Membranous nephropathy is the prototype of cancer-associated glomerulonephritis, with 10% of cases presenting with malignancy within a year from diagnosis. Among antigens that are expressed in patients with membranous nephropathy thrombospondin type 1 domain-containing 7A and neural epidermal growth factor-like-1 are often reported in patients with underlying malignancies. However, the risk of having a concurrent malignancy does not exceed 25%\u201330% when these antigens are expressed. While less frequent in other glomerulonephritides, co-occurrence of malignancy is reported in a substantial proportion of glomerular diseases including IgA nephropathy, podocytopathies with prominent podocyte foot process effacement such as minimal change disease as glomerular lesion pattern, amyloidosis, C3 glomerulopathy, monoclonal immunoglobulin deposition disease, or immune-complex-mediated glomerulonephritis. Treatment of malignancy-associated glomerulonephritis is usually directed toward treatment of the underlying malignancy with combinations of surgery, chemotherapy, and\/or radiotherapy. Moreover, relapse of the malignancy may result in recurrence of glomerulonephritis. Refractoriness of glomerulonephritis to initial therapy may be due to an occult primary malignancy that was not diagnosed during initial cancer screening. In such a scenario a step-up diagnostic approach is recommended. In addition, re-screening may be sensible for relapsing patients who carry higher risks for cancer including patients of older age and those with a smoking history. This review focuses on the description of malignancies in the context of glomerular diseases and provides practical guidance on screening.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf101","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T07:28:00Z","timestamp":1744183680000},"source":"Crossref","is-referenced-by-count":12,"title":["Malignancies and glomerulonephritis: when to suspect and when to screen?"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1948-2914","authenticated-orcid":false,"given":"Ahmet","family":"Murt","sequence":"first","affiliation":[{"name":"Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty Department of Nephrology Clinic, , Istanbul \u00a0","place":["Turkey"]},{"name":"Aziz Sancar Institute of Experimental Medicine, Istanbul University Department of Immunology, , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-7830","authenticated-orcid":false,"given":"Ilay","family":"Berke","sequence":"additional","affiliation":[{"name":"Nephrology and Hypertension, Medical University Innsbruck Department of Internal Medicine IV, , Innsbruck ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-9941","authenticated-orcid":false,"given":"Annette","family":"Bruchfeld","sequence":"additional","affiliation":[{"name":"Medicine and Caring Sciences, Link\u00f6ping University Department of Health, , Link\u00f6ping ,","place":["Sweden"]},{"name":"Karolinska University Hospital and CLINTEC Karolinska Institutet Department of Renal Medicine, , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-9663","authenticated-orcid":false,"given":"Fernando","family":"Caravaca-Font\u00e1n","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Rheinisch-Westf\u00e4lische Technische Hochschule (RWTH) Aachen University Hospital , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Frangou","sequence":"additional","affiliation":[{"name":"Limassol General Hospital Department of Nephrology, , Limassol , ; , Nicosia ,","place":["Cyprus Cyprus"]},{"name":"University of Nicosia Medical School Department of Nephrology, , Limassol , ; , Nicosia ,","place":["Cyprus Cyprus"]},{"name":"National and Kapodistrian University of Athens Medical School , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0362-8154","authenticated-orcid":false,"given":"Safak","family":"Mirioglu","sequence":"additional","affiliation":[{"name":"Aziz Sancar Institute of Experimental Medicine, Istanbul University Department of Immunology, , Istanbul ,","place":["Turkey"]},{"name":"Division of Nephrology, Bezmialem Vakif University Hospital , Istanbul ,","place":["Turkey"]},{"name":"Istanbul Faculty of Medicine, Istanbul University Division of Nephrology, Department of Internal Medicine, , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9377-4133","authenticated-orcid":false,"given":"Sarah M","family":"Moran","sequence":"additional","affiliation":[{"name":"Cork University Hospital, University College Cork , Cork ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-494X","authenticated-orcid":false,"given":"Stefanie","family":"Steiger","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians-University Hospital Munich Division of Nephrology, Department of Medicine IV, , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-1692","authenticated-orcid":false,"given":"Kate I","family":"Stevens","sequence":"additional","affiliation":[{"name":"Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-2195","authenticated-orcid":false,"given":"Onno Y K","family":"Teng","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Nephrology, , Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[{"name":"Nephrology and Hypertension, Medical University Innsbruck Department of Internal Medicine IV, , Innsbruck ,","place":["Austria"]},{"name":"Medicine and Caring Sciences, Link\u00f6ping University Department of Health, , Link\u00f6ping ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"2025050903564399500_bib1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"2025050903564399500_bib2","doi-asserted-by":"publisher","first-page":"886","DOI":"10.2215\/CJN.09000819","article-title":"Screening for cancer in patients with glomerular diseases","volume":"15","author":"Plaisier","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025050903564399500_bib3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12882-024-03632-9","article-title":"Nephrotic syndrome associated with solid malignancies: a systematic review","volume":"25","author":"Liu","year":"2024","journal-title":"BMC Nephrol"},{"key":"2025050903564399500_bib4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40620-015-0234-9","article-title":"Glomerular diseases and cancer: evaluation of underlying malignancy","volume":"29","author":"Pani","year":"2016","journal-title":"J Nephrol"},{"key":"2025050903564399500_bib5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1046\/j.1523-1755.1999.00548.x","article-title":"Paraneoplastic glomerulopathies: new insights into an old entity","volume":"56","author":"Ronco","year":"1999","journal-title":"Kidney Int"},{"key":"2025050903564399500_bib6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/8163298","article-title":"A novel insight into the role of PLA2R and THSD7A in membranous nephropathy","volume":"2021","author":"Zhang","year":"2021","journal-title":"J Immunol Res"},{"key":"2025050903564399500_bib7","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1054\/bjoc.2000.1496","article-title":"Application of positron emission tomography imaging to cancer screening","volume":"83","author":"Yasuda","year":"2000","journal-title":"Br J Cancer"},{"key":"2025050903564399500_bib8","doi-asserted-by":"publisher","first-page":"2355353","DOI":"10.1080\/0886022X.2024.2355353","article-title":"Prevalence and prognosis of malignancy in THSD7A-associated membranous nephropathy: a systematic literature review and clinical case study","volume":"46","author":"Xu","year":"2024","journal-title":"Ren Fail"},{"key":"2025050903564399500_bib9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"2025050903564399500_bib10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"key":"2025050903564399500_bib11","doi-asserted-by":"publisher","first-page":"sfae305","DOI":"10.1093\/ckj\/sfae305","article-title":"Why laser microdissection and mass spectrometry is the method of choice for detection of membranous nephropathy antigens","volume":"17","author":"Sethi","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025050903564399500_bib12","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-associated membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025050903564399500_bib13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"key":"2025050903564399500_bib14","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.3390\/jcm10194501","article-title":"Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment","volume":"10","author":"Knoppova","year":"2021","journal-title":"J Clin Med"},{"key":"2025050903564399500_bib15","first-page":"494","article-title":"[Paraneoplastic IgA nephritis as the initial symptom of bronchial carcinoma]","volume":"50","author":"Sch\u00fctte","year":"1996","journal-title":"Pneumologie"},{"key":"2025050903564399500_bib16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/MAJ.0b013e3181ae1b12","article-title":"Renal cell carcinoma in association with IgA nephropathy in the elderly","volume":"338","author":"Mimura","year":"2009","journal-title":"Am J Med Sci"},{"key":"2025050903564399500_bib17","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/sj.ki.5000341","article-title":"Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature","volume":"69","author":"Audard","year":"2006","journal-title":"Kidney Int"},{"key":"2025050903564399500_bib18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/pr.2016.200","article-title":"Idiopathic nephrotic syndrome: the EBV hypothesis","volume":"81","author":"Dossier","year":"2017","journal-title":"Pediatr Res"},{"key":"2025050903564399500_bib19","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00467-021-05386-0","article-title":"Benign and malignant proliferation in idiopathic nephrotic syndrome: a French cohort study","volume":"37","author":"C\u00e9bron","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"2025050903564399500_bib20","first-page":"1","article-title":"Cyclosporin A-sensitive nephrotic syndrome preceding Hodgkin's disease by 32 months","volume":"34","author":"Fouque","year":"1990","journal-title":"Clin Nephrol"},{"key":"2025050903564399500_bib21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40620-024-02084-6","article-title":"Minimal change glomerular disease associated with solid neoplasms: a systematic review","volume":"38","author":"Cozzo","year":"2024","journal-title":"J Nephrol"},{"key":"2025050903564399500_bib22","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/ckj\/sfab269","article-title":"An update of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"15","author":"Li","year":"2022","journal-title":"Clin Kidney J"},{"key":"2025050903564399500_bib23","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1053\/j.ajkd.2019.04.029","article-title":"Dysproteinemia and the kidney: core curriculum 2019","volume":"74","author":"Hogan","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2025050903564399500_bib24","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet"},{"key":"2025050903564399500_bib25","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-related disease","volume":"392","author":"Stone","year":"2025","journal-title":"N Engl J Med"},{"key":"2025050903564399500_bib26","doi-asserted-by":"publisher","first-page":"588","DOI":"10.2215\/CJN.0000000684","article-title":"IgG4-related kidney disease","volume":"20","author":"Ebrahimi","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025050903564399500_bib27","first-page":"26","article-title":"ANCA-associated glomerulonephritis: diagnosis and therapy proceedings of the Henry Shavelle Lectureship","volume":"5","author":"Ivkovi\u0107","year":"2025","journal-title":"Glomerular Dis"},{"key":"2025050903564399500_bib28","doi-asserted-by":"publisher","first-page":"101376","DOI":"10.1016\/j.tranon.2022.101376","article-title":"Critical evaluation of cancer risks in glomerular disease","volume":"19","author":"Thet","year":"2022","journal-title":"Transl Oncol"},{"key":"2025050903564399500_bib29","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s40620-023-01751-4","article-title":"Malignancy-associated membranous nephropathy: focus on diagnosis and treatment","volume":"36","author":"Ai","year":"2023","journal-title":"J Nephrol"},{"key":"2025050903564399500_bib30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0272-6386(12)70160-9","article-title":"Membranous glomerulonephritis and malignancy","volume":"22","author":"Burstein","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"2025050903564399500_bib31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12882-021-02457-0","article-title":"Recurrent membranous nephropathy with a possible alteration in the etiology: a case report","volume":"22","author":"Matsumoto","year":"2021","journal-title":"BMC Nephrol"},{"key":"2025050903564399500_bib32","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/sj.ki.5001790","article-title":"Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association","volume":"70","author":"Lefaucheur","year":"2006","journal-title":"Kidney Int"},{"key":"2025050903564399500_bib33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13730-020-00556-9","article-title":"Malignancy-associated membranous nephropathy with PLA2R double-positive for glomeruli and carcinoma","volume":"10","author":"Yasuda","year":"2021","journal-title":"CEN Case Rep"},{"key":"2025050903564399500_bib34","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1136\/jclinpath-2019-205852","article-title":"Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy","volume":"72","author":"Zhang","year":"2019","journal-title":"J Clin Pathol"},{"key":"2025050903564399500_bib35","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1681\/ASN.2010090967","article-title":"Anti-phospholipase A2 receptor antibody in membranous nephropathy","volume":"22","author":"Qin","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025050903564399500_bib36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.11860720","article-title":"Neural Epidermal Growth Factor-Like 1 Protein-positive membranous nephropathy in Chinese patients","volume":"16","author":"Wang","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025050903564399500_bib37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/1936372","article-title":"Recent Progress in deciphering the etiopathogenesis of primary membranous nephropathy","volume":"2017","author":"Kronbichler","year":"2017","journal-title":"Biomed Res Int"},{"key":"2025050903564399500_bib38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"2025050903564399500_bib39","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025050903564399500_bib40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12882-019-1489-5","article-title":"Expression of THSD7A in neoplasm tissues and its relationship with proteinuria","volume":"20","author":"Xian","year":"2019","journal-title":"BMC Nephrol"},{"key":"2025050903564399500_bib41","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A mechanism for cancer-associated membranous nephropathy","volume":"374","author":"Hoxha","year":"2016","journal-title":"N Engl J Med"},{"key":"2025050903564399500_bib42","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1007\/s005950070014","article-title":"Membranous glomerulonephritis associated with diffuse malignant pleural mesothelioma: report of a case","volume":"30","author":"Sakamoto","year":"2000","journal-title":"Surg Today"},{"key":"2025050903564399500_bib43","doi-asserted-by":"publisher","first-page":"e16649","DOI":"10.1097\/MD.0000000000016649","article-title":"Recurrent anti-GBM disease with T-cell large granular lymphocytic leukemia: a case report","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025050903564399500_bib44","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s13730-021-00648-0","article-title":"Long-term clinical course of immunotactoid glomerulopathy complicated with diffuse large B-cell lymphoma","volume":"11","author":"Takahashi","year":"2022","journal-title":"CEN Case Rep"},{"key":"2025050903564399500_bib45","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000520399","article-title":"Malignancy-associated membranous nephropathy with positive anti-PLA2R autoantibodies: coincidence or connection","volume":"11","author":"Baker","year":"2021","journal-title":"Case Rep Nephrol Dial"},{"key":"2025050903564399500_bib46","doi-asserted-by":"publisher","first-page":"111327","DOI":"10.1016\/j.intimp.2023.111327","article-title":"Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy","volume":"126","author":"Guo","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2025050903564399500_bib47","doi-asserted-by":"publisher","first-page":"1156470","DOI":"10.3389\/fimmu.2023.1156470","article-title":"Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"2025050903564399500_bib48","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis","volume":"403","author":"Kronbichler","year":"2024","journal-title":"Lancet"},{"key":"2025050903564399500_bib49","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025050903564399500_bib50","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025050903564399500_bib51","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3899\/jrheum.160885","article-title":"Incidence of malignancy prior to antineutrophil cytoplasmic antibody-associated vasculitis compared to the general population","volume":"44","author":"van Daalen","year":"2017","journal-title":"J Rheumatol"},{"key":"2025050903564399500_bib52","doi-asserted-by":"publisher","first-page":"300060521993319","DOI":"10.1177\/0300060521993319","article-title":"Lung adenocarcinoma and sequential antineutrophil cytoplasmic antibody-associated vasculitis: a case report","volume":"49","author":"Zhang","year":"2021","journal-title":"J Int Med Res"},{"key":"2025050903564399500_bib53","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/pgmj.64.751.395","article-title":"Glomerulonephritis preceding late relapse of Hodgkin's disease","volume":"64","author":"Lynn","year":"1988","journal-title":"Postgrad Med J"},{"key":"2025050903564399500_bib54","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0272-6386(12)70288-3","article-title":"The successful treatment of recurrent nephrotic syndrome with the MOPP regimen in a patient with a remote history of Hodgkin's disease","volume":"23","author":"Delmez","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"2025050903564399500_bib55","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/ckj\/sfac261","article-title":"Backtracking cryptic recurrence of esophageal cancer from membranous nephropathy: the detection of glomerular NELL-1 and IgG4","volume":"16","author":"Zhou","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025050903564399500_bib56","first-page":"853","article-title":"Immunoglobulin A nephropathy could be a clue for the recurrence of gastric adenocarcinoma","volume":"33","author":"Kocyigit","year":"2013","journal-title":"Nefrologia"},{"key":"2025050903564399500_bib57","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5114\/ceji.2023.127744","article-title":"An unusual cause of rapidly progressive glomerulonephritis associated with ANCA vasculitis and ovarian malignancy\u2014a relapse 39 years after initial treatment","volume":"48","author":"Simovic","year":"2023","journal-title":"Cent Eur J Immunol"},{"key":"2025050903564399500_bib58","first-page":"626","article-title":"Focal segmental glomerulosclerosis due to a relapsing non-Hodgkin's lymphoma diagnosed by positron emission tomography","volume":"20","author":"Gonz\u00e1lez Garc\u00eda","year":"2007","journal-title":"J Nephrol"},{"key":"2025050903564399500_bib59","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s13730-023-00807-5","article-title":"A case of paraneoplastic IgA nephropathy with glomerular capillary IgA and galactose-deficient IgA1 deposition","volume":"13","author":"Isogai","year":"2024","journal-title":"CEN Case Rep"},{"key":"2025050903564399500_bib60","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12882-021-02479-8","article-title":"Efficacy of rituximab in thymoma associated minimal change disease: case report","volume":"22","author":"El Ouafi","year":"2021","journal-title":"BMC Nephrol"},{"key":"2025050903564399500_bib61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12882-019-1236-y","article-title":"Thrombospondin type-1 domain-containing 7A-associated membranous nephropathy after resection of rectal cancer: a case report","volume":"20","author":"Taguchi","year":"2019","journal-title":"BMC Nephrol"},{"key":"2025050903564399500_bib62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ajkd.2021.03.027","article-title":"ANCA-negative pauci-immune necrotizing glomerulonephritis: a case series and a new clinical classification","volume":"79","author":"Ronsin","year":"2022","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf101\/62907972\/sfaf101.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/5\/sfaf101\/62907972\/sfaf101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/5\/sfaf101\/62907972\/sfaf101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T03:57:00Z","timestamp":1746763020000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf101\/8110696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf101","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,10]]},"article-number":"sfaf101"}}